The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer.

Nivolumab improves the survival of advanced non-small cell lung cancer (NSCLC), but a significant number of patients still fail to benefit from this treatment. In this study, we evaluated the efficacy of the time-series behavior of neutrophil-to-lymphocyte ratio (NLR) in a complete blood count from...

Full description

Bibliographic Details
Main Authors: Tatsunori Kiriu, Masatsugu Yamamoto, Tatsuya Nagano, Daisuke Hazama, Reina Sekiya, Masahiro Katsurada, Daisuke Tamura, Motoko Tachihara, Kazuyuki Kobayashi, Yoshihiro Nishimura
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5814002?pdf=render
id doaj-9bfaf406d5e247d695c72028e36e1af8
record_format Article
spelling doaj-9bfaf406d5e247d695c72028e36e1af82020-11-24T21:50:35ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01132e019301810.1371/journal.pone.0193018The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer.Tatsunori KiriuMasatsugu YamamotoTatsuya NaganoDaisuke HazamaReina SekiyaMasahiro KatsuradaDaisuke TamuraMotoko TachiharaKazuyuki KobayashiYoshihiro NishimuraNivolumab improves the survival of advanced non-small cell lung cancer (NSCLC), but a significant number of patients still fail to benefit from this treatment. In this study, we evaluated the efficacy of the time-series behavior of neutrophil-to-lymphocyte ratio (NLR) in a complete blood count from advanced NSCLC patients as a predictive marker of the anticancer effect of nivolumab.We performed a retrospective review of medical records and collected data on patients with advanced NSCLC treated with nivolumab as second- and further-line treatments from December 2015 to March 2017. The NLRs were calculated before each treatment cycle for four cycles. These parameters were tested for its association with the overall survival (OS), progression-free survival (PFS) and time to treatment failure (TTF).Nineteen patients were treated with nivolumab. Stratified by the response to nivolumab, the median OS was 2.8 months in progressive disease (PD) and 14.0 months in non-PD (p = 0.002). Before discontinuation of PD or toxicity, an NLR is rising from baseline in 5 out of 7 patients with PD and all of 4 patients with discontinuation due to toxicity. Patients with an >30% increase in NLR were associated with a significantly shorter TTF compared with those with stable or decrease in NLR both after first cycle (p = 0.014) and second cycle (p < 0.001).The NLR is suggested to be useful not only as a prognostic marker but also as a predictive marker for treatment with nivolumab. Further prospective study is warranted to develop a predictive algorithm to detect PD cases as early as possible by focusing the time-series behavior of NLR.http://europepmc.org/articles/PMC5814002?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Tatsunori Kiriu
Masatsugu Yamamoto
Tatsuya Nagano
Daisuke Hazama
Reina Sekiya
Masahiro Katsurada
Daisuke Tamura
Motoko Tachihara
Kazuyuki Kobayashi
Yoshihiro Nishimura
spellingShingle Tatsunori Kiriu
Masatsugu Yamamoto
Tatsuya Nagano
Daisuke Hazama
Reina Sekiya
Masahiro Katsurada
Daisuke Tamura
Motoko Tachihara
Kazuyuki Kobayashi
Yoshihiro Nishimura
The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer.
PLoS ONE
author_facet Tatsunori Kiriu
Masatsugu Yamamoto
Tatsuya Nagano
Daisuke Hazama
Reina Sekiya
Masahiro Katsurada
Daisuke Tamura
Motoko Tachihara
Kazuyuki Kobayashi
Yoshihiro Nishimura
author_sort Tatsunori Kiriu
title The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer.
title_short The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer.
title_full The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer.
title_fullStr The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer.
title_full_unstemmed The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer.
title_sort time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2018-01-01
description Nivolumab improves the survival of advanced non-small cell lung cancer (NSCLC), but a significant number of patients still fail to benefit from this treatment. In this study, we evaluated the efficacy of the time-series behavior of neutrophil-to-lymphocyte ratio (NLR) in a complete blood count from advanced NSCLC patients as a predictive marker of the anticancer effect of nivolumab.We performed a retrospective review of medical records and collected data on patients with advanced NSCLC treated with nivolumab as second- and further-line treatments from December 2015 to March 2017. The NLRs were calculated before each treatment cycle for four cycles. These parameters were tested for its association with the overall survival (OS), progression-free survival (PFS) and time to treatment failure (TTF).Nineteen patients were treated with nivolumab. Stratified by the response to nivolumab, the median OS was 2.8 months in progressive disease (PD) and 14.0 months in non-PD (p = 0.002). Before discontinuation of PD or toxicity, an NLR is rising from baseline in 5 out of 7 patients with PD and all of 4 patients with discontinuation due to toxicity. Patients with an >30% increase in NLR were associated with a significantly shorter TTF compared with those with stable or decrease in NLR both after first cycle (p = 0.014) and second cycle (p < 0.001).The NLR is suggested to be useful not only as a prognostic marker but also as a predictive marker for treatment with nivolumab. Further prospective study is warranted to develop a predictive algorithm to detect PD cases as early as possible by focusing the time-series behavior of NLR.
url http://europepmc.org/articles/PMC5814002?pdf=render
work_keys_str_mv AT tatsunorikiriu thetimeseriesbehaviorofneutrophiltolymphocyteratioisusefulasapredictivemarkerinnonsmallcelllungcancer
AT masatsuguyamamoto thetimeseriesbehaviorofneutrophiltolymphocyteratioisusefulasapredictivemarkerinnonsmallcelllungcancer
AT tatsuyanagano thetimeseriesbehaviorofneutrophiltolymphocyteratioisusefulasapredictivemarkerinnonsmallcelllungcancer
AT daisukehazama thetimeseriesbehaviorofneutrophiltolymphocyteratioisusefulasapredictivemarkerinnonsmallcelllungcancer
AT reinasekiya thetimeseriesbehaviorofneutrophiltolymphocyteratioisusefulasapredictivemarkerinnonsmallcelllungcancer
AT masahirokatsurada thetimeseriesbehaviorofneutrophiltolymphocyteratioisusefulasapredictivemarkerinnonsmallcelllungcancer
AT daisuketamura thetimeseriesbehaviorofneutrophiltolymphocyteratioisusefulasapredictivemarkerinnonsmallcelllungcancer
AT motokotachihara thetimeseriesbehaviorofneutrophiltolymphocyteratioisusefulasapredictivemarkerinnonsmallcelllungcancer
AT kazuyukikobayashi thetimeseriesbehaviorofneutrophiltolymphocyteratioisusefulasapredictivemarkerinnonsmallcelllungcancer
AT yoshihironishimura thetimeseriesbehaviorofneutrophiltolymphocyteratioisusefulasapredictivemarkerinnonsmallcelllungcancer
AT tatsunorikiriu timeseriesbehaviorofneutrophiltolymphocyteratioisusefulasapredictivemarkerinnonsmallcelllungcancer
AT masatsuguyamamoto timeseriesbehaviorofneutrophiltolymphocyteratioisusefulasapredictivemarkerinnonsmallcelllungcancer
AT tatsuyanagano timeseriesbehaviorofneutrophiltolymphocyteratioisusefulasapredictivemarkerinnonsmallcelllungcancer
AT daisukehazama timeseriesbehaviorofneutrophiltolymphocyteratioisusefulasapredictivemarkerinnonsmallcelllungcancer
AT reinasekiya timeseriesbehaviorofneutrophiltolymphocyteratioisusefulasapredictivemarkerinnonsmallcelllungcancer
AT masahirokatsurada timeseriesbehaviorofneutrophiltolymphocyteratioisusefulasapredictivemarkerinnonsmallcelllungcancer
AT daisuketamura timeseriesbehaviorofneutrophiltolymphocyteratioisusefulasapredictivemarkerinnonsmallcelllungcancer
AT motokotachihara timeseriesbehaviorofneutrophiltolymphocyteratioisusefulasapredictivemarkerinnonsmallcelllungcancer
AT kazuyukikobayashi timeseriesbehaviorofneutrophiltolymphocyteratioisusefulasapredictivemarkerinnonsmallcelllungcancer
AT yoshihironishimura timeseriesbehaviorofneutrophiltolymphocyteratioisusefulasapredictivemarkerinnonsmallcelllungcancer
_version_ 1725882915013787648